Clorox Q1 FY27: Sales Up 33% to $1.91B, Adjusted EPS $1.55; Outlook Skews to Low End
CLX sits 19% above its 52-week low of $79.12.
Summary
Clorox reported Q1 FY27 sales of $1.91B (+33%) and adjusted EPS of $1.55, but held its FY27 ranges while steering adjusted EPS toward the low end on higher inflation and a lower gross margin outlook.
Key Events · Earnings and Guidance · CLX
-
Q1 FY27 Sales Jump 33%
Net sales rose 33% to $1.91 billion, including about 15 points from the GOJO acquisition; organic sales increased 18%, boosted by lapping the prior-year ERP inventory drawdown.
-
Adjusted EPS More Than Doubles
Adjusted EPS was $1.55 versus $0.85 a year ago (+82%), and GAAP diluted EPS was $1.39 versus $0.65 (+114%), helped by the easy prior-year comparison and a lower tax rate.
-
Gross Margin Falls 130 bps
Gross margin declined to 40.4% from 41.7% on higher commodity, manufacturing and logistics costs, partly offset by volume and cost savings; GOJO inventory step-up cost about 50 basis points.
-
FY27 Outlook Skews to Low End
Sales growth guidance of 13%-14% and adjusted EPS of $5.70-$6.00 were maintained, but adjusted EPS is now expected near the low end and gross margin guidance was cut to about 41.5% on inflation.
Analysis · CLX · Industrial Applications And Services
Clorox beat on the quarter but flagged a tougher cost backdrop. Net sales rose 33% to $1.91 billion, with about 15 points from the GOJO acquisition and organic sales up 18% largely because the year-ago quarter was depressed by the ERP inventory drawdown. Adjusted EPS of $1.55 more than doubled from $0.85, again flattered by that easy comparison. The real news is the outlook: sales and adjusted EPS ranges were maintained, but management now expects adjusted EPS near the low end of $5.70-$6.00 and cut its gross margin expectation to about 41.5% on higher inflation and negative mix. Gross margin already fell 130 basis points to 40.4% in the quarter. With debt at roughly $5.1 billion after GOJO and a CEO transition to Fabian Garcia set for January 5, 2027, cost pressure is the near-term swing factor for the stock.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLX was trading at $94.25 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $10.9B. The 52-week trading range was $79.12 to $128.90. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.